MaxCyte: Firing on all cylinders
MXCT made outstanding progress in H1 20 across the business and is set to report revenue growth of c 30% to $10.9mln ($8.4mln in H1 19). Trading reflected the solid progress made in MXCT’s cell therapy business, which is focused on driving adoption of its nonviral cell engineering technology Flow Electroporation across its ExPERT instrument platform. Since the start of the year, MXCT has signed three out of 11 clinical and commercial licences with leaders in the cell therapy space. The company’s wholly-owned therapeutic subsidiary, CARMA, is on target for achieving independent funding in 2020, and this can crystallise its value, given the strong appetite and interest in the broader regenerative medicine space which attracted $9.8bn of global financing in 2019.
Quick facts: MaxCyte Inc
Price: 310 GBX
Market Cap: £239.2 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE